Never say die: survival signaling in large granular lymphocyte leukemia.

Large granular lymphocyte (LGL) leukemia is a rare disorder of mature cytotoxic T or natural killer cells. Large granular lymphocyte leukemia is characterized by the accumulation of cytotoxic cells in blood and infiltration in the bone marrow, liver, and spleen. Herein, we review clinical features of LGL leukemia. We focus our discussion on known survival signals believed to play a role in the pathogenesis of LGL leukemia and their potential therapeutic implications.

[1]  S. Spiegel,et al.  Sphingosine‐1‐Phosphate in Cell Growth and Cell Death a , 1998, Annals of the New York Academy of Sciences.

[2]  Sheng Wei,et al.  Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. , 2007, Blood.

[3]  Thierry Lamy,et al.  Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. , 2002, Blood.

[4]  E. Goetzl,et al.  Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. , 1999, Journal of immunology.

[5]  David Baltimore,et al.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences , 1986, Cell.

[6]  V. Brinkmann.  Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.

[7]  S. Ghosh,et al.  NF-κB and the immune response , 2006, Oncogene.

[8]  A. Villanueva,et al.  Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo , 2007, Oncogene.

[9]  R. Albert,et al.  Systems-level insights into cellular regulation: inferring, analysing, and modelling intracellular networks. , 2007, IET systems biology.

[10]  Sheng Wei,et al.  Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. , 2008, Blood.

[11]  M. Vadas,et al.  Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling , 2005, The Journal of experimental medicine.

[12]  R. Kolesnick.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway. , 2002, The Journal of clinical investigation.

[13]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  A. Hoffmann,et al.  Circuitry of nuclear factor κB signaling , 2006 .

[15]  N. Dhanasekaran,et al.  Neoplastic transformation by the gep oncogene, Gα12, involves signaling by STAT3 , 2006, Oncogene.

[16]  J. Armand,et al.  The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. , 2007, The oncologist.

[17]  Ranran Zhang,et al.  Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. , 2008, Blood.

[18]  V. L. Johnson,et al.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas‐mediated apoptosis downstream of DISC assembly , 2000, The EMBO journal.

[19]  S. Pyne,et al.  Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. , 2002, Biochimica et biophysica acta.

[20]  L. Samelson,et al.  Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. , 2002, Annual review of immunology.

[21]  T. Loughran,et al.  Clinical features of large granular lymphocyte leukemia. , 2003, Seminars in hematology.

[22]  Margot Thome,et al.  Regulation of lymphocyte proliferation and death by flip , 2001, Nature Reviews Immunology.

[23]  K. Yoshino,et al.  Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .

[24]  R. Widen,et al.  Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome , 2007, Leukemia.

[25]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[26]  S. Milstien,et al.  Sphingosine 1-Phosphate, a Key Cell Signaling Molecule* , 2002, The Journal of Biological Chemistry.

[27]  M. Wlodarski,et al.  Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. , 2005, Blood.

[28]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[29]  L. McDonald,et al.  A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic Lymphocytes* , 1996, The Journal of Biological Chemistry.

[30]  D. Coppola,et al.  Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice , 2000, Nature Biotechnology.

[31]  A. Strasser,et al.  Interleukin 15–mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1 , 2007, Nature Immunology.

[32]  Jian Zhang,et al.  Activation-induced cell death in T cells and autoimmunity. , 2004, Cellular & molecular immunology.

[33]  M. Lim,et al.  Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms , 2009, Journal of hematopathology.

[34]  Barbara S. Paugh,et al.  A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. , 2008, Blood.

[35]  Y. Zhuang,et al.  Antitumor Activity of Sphingosine Kinase Inhibitors , 2006, Journal of Pharmacology and Experimental Therapeutics.

[36]  Stephen L. Abrams,et al.  Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia , 2008, Leukemia.

[37]  S. Latour,et al.  Negative regulation of immunoreceptor signaling. , 2002, Annual review of immunology.

[38]  D. Levy,et al.  STAT3: A multifaceted oncogene , 2006, Proceedings of the National Academy of Sciences.

[39]  J. H. Liu,et al.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. , 1998, Blood.

[40]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[41]  J. Tschopp,et al.  cFLIP regulation of lymphocyte activation and development , 2006, Nature Reviews Immunology.

[42]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[43]  Yiling Lu,et al.  Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. , 2006, Cancer cell.

[44]  R. Albert,et al.  Network model of survival signaling in large granular lymphocyte leukemia , 2008, Proceedings of the National Academy of Sciences.

[45]  T. Fleisher.  The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis , 2008, Immunologic research.

[46]  T. Loughran,et al.  Current concepts: large granular lymphocyte leukemia. , 1999, Blood reviews.

[47]  C. Riccardi,et al.  Cloning and expression of a short Fas ligand: A new alternatively spliced product of the mouse Fas ligand gene. , 1999, Blood.

[48]  C. Beam,et al.  Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. , 2005, Blood.

[49]  Y. Wan,et al.  The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. , 2003, Immunity.

[50]  Irina Kusmartseva,et al.  Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. , 2002, Biochimica et biophysica acta.

[51]  I. Berge,et al.  Human CD8+ T-cell differentiation in response to viruses , 2003, Nature Reviews Immunology.

[52]  C. Disteche,et al.  Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. , 1985, Annals of internal medicine.

[53]  J. Turkson,et al.  Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. , 2004, Molecular cancer therapeutics.

[54]  Jae-Ho Park,et al.  Acid ceramidase and human disease. , 2006, Biochimica et biophysica acta.

[55]  Sheng Wei,et al.  ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL) , 2004, Oncogene.

[56]  G. Xiao,et al.  The NF-κB Signaling Pathway Is Not Required for Fas Ligand Gene Induction but Mediates Protection from Activation-induced Cell Death* , 2000, The Journal of Biological Chemistry.

[57]  M. Philips,et al.  Compartmentalized Ras/MAPK signaling. , 2006, Annual review of immunology.

[58]  T. Loughran,et al.  Large Granular Lymphocyte Leukemia. , 1998, Cancer Control: Journal of the Moffitt Cancer Cente.

[59]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[60]  W. Kisiel,et al.  Molecular Cloning, Expression, and Partial Characterization of Two Novel Members of the Ovalbumin Family of Serine Proteinase Inhibitors (*) , 1995, The Journal of Biological Chemistry.

[61]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[62]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[63]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[64]  Michael J. Parsons,et al.  CD28-dependent Activation of Protein Kinase B/Akt Blocks Fas-mediated Apoptosis by Preventing Death-inducing Signaling Complex Assembly , 2002, The Journal of experimental medicine.

[65]  T. Loughran,et al.  Clonal diseases of large granular lymphocytes. , 1993, Blood.

[66]  A. Strasser,et al.  Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. , 1995, Genes & development.

[67]  G. Fiume,et al.  The aftermath of the Merck's HIV vaccine trial , 2008, Retrovirology.

[68]  Michael Y. Gerner,et al.  Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. , 2007, Seminars in cancer biology.

[69]  T. Loughran,et al.  Large granular lymphocyte leukemia , 2007, Current hematologic malignancy reports.

[70]  E. Goetzl,et al.  Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network , 2005, Nature Reviews Immunology.

[71]  P. Krammer,et al.  The CD95 system and the death of a lymphocyte. , 1997, Seminars in immunology.

[72]  A Krueger,et al.  The active caspase-8 heterotetramer is formed at the CD95 DISC , 2003, Cell Death and Differentiation.

[73]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  J. Cyster,et al.  Finding a way out: lymphocyte egress from lymphoid organs , 2007, Nature Immunology.

[75]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[76]  J. Trapani,et al.  Unlocking the secrets of cytotoxic granule proteins , 2001, Journal of leukocyte biology.

[77]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[78]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[79]  T. Rogers,et al.  The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B–dependent hepatotoxicity , 2007, Hepatology.

[80]  R. Albert,et al.  Predicting Essential Components of Signal Transduction Networks: A Dynamic Model of Guard Cell Abscisic Acid Signaling , 2006, PLoS biology.

[81]  S. Milstien,et al.  Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. , 2006, Cancer cell.

[82]  R. Schneiter,et al.  Lipid signalling in disease , 2008, Nature Reviews Molecular Cell Biology.

[83]  S. Spiegel,et al.  Sphingosine 1-Phosphate Inhibits Activation of Caspases that Cleave Poly(ADP-ribose) Polymerase and Lamins during Fas- and Ceramide-mediated Apoptosis in Jurkat T Lymphocytes* , 1998, The Journal of Biological Chemistry.

[84]  K. Hess,et al.  A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo , 2007, Oncogene.

[85]  Jun Yao,et al.  Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. , 2006, Cancer research.

[86]  D. Levy,et al.  What does Stat3 do? , 2002, The Journal of clinical investigation.

[87]  M. Bevan,et al.  Effector and memory CTL differentiation. , 2007, Annual review of immunology.